Inhalation therapy
The respiratory system is in a special though not unique position with respect to therapy, particularly when treating conditions associated with airways obstruction. A variety of drugs may be administered directly rather than by a more circuitous route, achieving a maximum effect with a very much smaller dosage when compared to oral administration of a similar drug. Unwanted side effects are kept to a minimum. As far as bronchodilatation is concerned other advantages include the rapid onset of action with peak effect which is reached far sooner than in the case of oral bronchodilators; a duration of action comparable with oral therapy; and in patients with intermittent rather than chronic airways obstruction, a reliable method of obtaining relief as and when 0141-0768/80/110769-02/$01.00/0 necessary, rather than continuous oral therapy some of which will be unnecessary.
Despite the obvious advantage of inhaled therapy, oral bronchodilators retain their popularity throughout the spectrum of conditions associated with airways obstruction. Many clinicians, especially in general practice, and many patients, seem reluctant to use inhaled drugs of any sort. One can appreciate that their fears are related to the 'epidemic' of asthma deaths in the United Kingdom in the I960s, which it was origially suggested was due to excessive use of isoprenaline-containing aerosols. The evidence which has become available since then has not borne out this suggestion. A more plausible explanation is the development of resistance to beta-adrenoceptor stimulants, with diminution of effective endogenous sympathetic drive to the bronchi on which asthmatics rely to maintain effective bronchodilatation (Conolly et al. 1971) . Be that as it may, abuse of bronchodilator aerosols is undoubtedly a dangerous practice.
There are many factors which influence the therapeutic activity of a drug delivered by pressurized aerosol. The composition of the drug and propellant, the physical characteristics of the delivery system, and to some extent the magnitude and distribution of the patient's inspiratory airflow can be controlled. In connection with the last, how important is the development of a 'correct' technique in the use of pressurized aerosols? In this issue Newman et al. (page 000) offer a convincing demonstration in their patients under controlled conditions that a slow, deep inhalation of terbutaline sulphate with a tensecond breath-holding pause, irrespective of the lung volume at which the aerosol is inhaled, offers the best chance of maximal bronchodilatation. Their methods are reliable and their proposals are worthy of serious consideration. How applicable such laboratory investigations are to the clinical situation is, however, less certain. Many patients in urgent need of relief may be unable to follow either of the principal instructions. Further, any benefits to the patients from improved technique are likely to be as great, if not greater, from more efficient use of topical steroid treatment delivered by aerosol.
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